Download PDF
Exp Clin Endocrinol Diabetes 2016; 124(03): 203-207
DOI: 10.1055/s-0035-1565060
Article
© Georg Thieme Verlag KG Stuttgart · New York

Serum Irisin Level is Higher and Related with Insulin in Acanthosis Nigricans-related Obesity

J. Q. Chen
1   Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine Tongji University, Shanghai, China
2   Nanjing Medical University, Nanjing, Jiangsu, China
,
L. J. Fang
2   Nanjing Medical University, Nanjing, Jiangsu, China
,
K. X. Song
1   Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine Tongji University, Shanghai, China
,
X. C. Wang
1   Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine Tongji University, Shanghai, China
2   Nanjing Medical University, Nanjing, Jiangsu, China
,
Y. Y. Huang
1   Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine Tongji University, Shanghai, China
,
S. Y. Chai
1   Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine Tongji University, Shanghai, China
,
L. Bu
1   Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine Tongji University, Shanghai, China
,
S. Qu
1   Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, School of Medicine Tongji University, Shanghai, China
2   Nanjing Medical University, Nanjing, Jiangsu, China
› Author Affiliations
Further Information

Publication History

received 16 June 2015
first decision 19 August 2015

accepted 23 September 2015

Publication Date:
20 November 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Objective: Acanthosis nigricans (AN) is proved to be a skin phenotype of hyperinsulinemia especially in obese patients. Irisin is a new myokine which plays an important role in metabolic disorders, such as obesity, insulin resistance, and type 2 diabetes. The role of irisin in the development of AN-related obesity is not yet understood. In this study, we aimed to investigate the relationship between irisin and AN-related obesity.

Patients & Measurements: 30 obese patients without AN (OB group), 30 obese patients with AN (AN group), and 20 age-matched healthy volunteers (control group, CON) were included in this study. Weight, BMI, lipid profile, FFA, UA, and CRP were measured in all participants. Oral Glucose Tolerance tests (OGTT) were performed and serum glucose and plasma insulin were measured at 0, 30, 60,120 and 180 min. The AUC (area under curve) of glucose and insulin was calculated. Serum irisin was measured by ELISA.

Results: Hyperinsulinemia is found in both AN and OB groups. The AN group had higher levels of insulin but better blood glucose tolerance and insulin response. The difference in irisin levels between the 3 groups was statistically significant, with the AN group showing the highest serum level of irisin. Serum irisin levels were positively correlated with BMI, and fasting insulin.

Conclusion: AN is a state of hyperinsulinmia and has better insulin response and glucose tolerance compared to obese patients without AN. Serum irisin may be a protective factor against impaired beta cell function in obesity with AN.

Key words

irisin - acanthosis nigricans - obesity - hyperinsulinemia
 

  • References

  • 1 Jones LH, Ficca M. Is Acanthosis Nigricans a reliable indicator for risk of type 2 diabetes?. J Sch Nurs 2007; 23: 247-251
    CrossrefPubMedGoogle Scholar
  • 2 Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol 2007; 57: 502-508
    CrossrefPubMedGoogle Scholar
  • 3 Bostrom P, Wu J, Jedrychowski MP et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468
    CrossrefPubMedGoogle Scholar
  • 4 Liu JJ, Wong MD, Toy WC et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 365-369
    CrossrefPubMedGoogle Scholar
  • 5 Huh JY, Panagiotou G, Mougios V et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. MRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725-1738
    CrossrefPubMedGoogle Scholar
  • 6 Crujeiras AB, Pardo M, Arturo RR et al. Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Um Biol 2014; 26: 198-207
    PubMedGoogle Scholar
  • 7 de la Iglesia R, Lopez-Legarrea P, Crujeiras AB et al. Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clin Endocrinol (Oxf) 2014; 81: 306-311
    CrossrefPubMedGoogle Scholar
  • 8 Choi YK, Kim MK, Bae KH et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101
    CrossrefPubMedGoogle Scholar
  • 9 Moreno-Navarrete JM, Ortega F, Serrano M et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769-E778
    CrossrefPubMedGoogle Scholar
  • 10 Xiang L, Xiang G, Yue L et al. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis 2014; 235: 328-333
    CrossrefPubMedGoogle Scholar
  • 11 Zhang M, Chen P, Chen S et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: A preliminary study. Eur Rev Med Pharmacol Sci 2014; 18: 1567-1572
    PubMedGoogle Scholar
  • 12 Burke JP, Hale DE, Hazuda HP et al. A quantitative scale of acanthosis nigricans. Diabetes Care 1999; 22: 1655-1659
    CrossrefPubMedGoogle Scholar
  • 13 Zaridoust A, Rabbani A, Sayarifard F et al. Acanthosis nigricans, abnormal facial appearance and dentition in an insulin resistance syndrome. Iran J Pediatr 2013; 23: 363-365
    PubMedGoogle Scholar
  • 14 Kluczynik CE, Mariz LS, Souza LC et al. Acanthosis nigricans and insulin resistance in overweight children and adolescents. An Bras Dermatol 2012; 87: 531-537
    CrossrefPubMedGoogle Scholar
  • 15 Guilherme A, Virbasius JV, Puri V et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377
    CrossrefPubMedGoogle Scholar
  • 16 Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 2008; 454: 463-469
    CrossrefPubMedGoogle Scholar
  • 17 Yan J, Feng Z, Liu J et al. Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: Ameliorating effects of (-)-epigallocatechin-3-gallate. J Nutr Biochem 2012; 23: 716-724
    CrossrefPubMedGoogle Scholar
  • 18 Guilherme A, Virbasius JV, Puri V et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377
    CrossrefPubMedGoogle Scholar
  • 19 Holloszy JO. Skeletal muscle “mitochondrial deficiency” does not mediate insulin resistance. Am J Clin Nutr 2009; 89: 463S-466S
    PubMedGoogle Scholar
  • 20 Jackson JR, Ryan MJ, Alway SE. Long-term supplementation with resveratrol alleviates oxidative stress but does not attenuate sarcopenia in aged mice. J Gerontol A Biol Sci Med Sci 2011; 66: 751-764
    PubMedGoogle Scholar
  • 21 Muoio DM, Koves TR. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 alpha: Implications for metabolic disease. Appl Physiol Nutr Metab 2007; 32: 874-883
    CrossrefPubMedGoogle Scholar
  • 22 Hee PK, Zaichenko L, Brinkoetter M et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899-4907
    CrossrefPubMedGoogle Scholar
  • 23 Stengel A, Hofmann T, Goebel-Stengel M et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – correlation with body mass index. Peptides 2013; 39: 125-130
    CrossrefPubMedGoogle Scholar
  • 24 Pardo M, Crujeiras AB, Amil M et al. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol. 2014 2014. 857270
    PubMedGoogle Scholar
  • 25 Liu JJ, Liu S, Wong MD et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complications 2014; 28: 208-213
    CrossrefPubMedGoogle Scholar
  • 26 Masoodi M, Kuda O, Rossmeisl M et al. Lipid signaling in adipose tissue: Connecting inflammation & metabolism. Biochim Biophys Acta 2014;
    PubMedGoogle Scholar
  • 27 Sanz Y, Moya-Perez A. Microbiota inflammation and obesity. Adv Exp Med Biol 2014; 817: 291-317
    PubMedGoogle Scholar
  • 28 Panagiotou G, Mu L, Na B et al. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism 2014; 63: 1265-1271
    CrossrefPubMedGoogle Scholar
  • 29 Zhang HJ, Zhang XF, Ma ZM et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol 2013; 59: 557-562
    CrossrefPubMedGoogle Scholar